Clinical Scorecard: Rapid Progression of Therapy-Related Myelodysplastic Syndrome to Acute Myeloid Leukemia After CAR-T Cell Treatment in a Patient with Refractory Diffuse Large B-Cell Lymphoma: A Case Study

At a Glance

Key Highlights

• Persistent cytopenia can indicate underlying therapy-related myeloid neoplasms.
• Diagnosis of therapy-related myelodysplastic syndrome established through comprehensive bone marrow evaluation.
• Rapid progression from therapy-related myelodysplastic syndrome to acute myeloid leukemia observed within two months.
• Combination therapy with azacitidine and venetoclax was initiated but discontinued due to severe myelosuppression.
• Critical need for vigilant bone marrow surveillance in patients with extensive prior cytotoxic therapy.

Guideline-Based Recommendations

Diagnosis

• Comprehensive bone marrow assessments including morphology, flow cytometry, cytogenetics, and molecular profiling.

Management

• Consideration of therapy-related myeloid neoplasms in patients with prolonged, transfusion-refractory cytopenias.

Monitoring & Follow-up

• Regular monitoring for signs of myelodysplastic syndrome and acute myeloid leukemia in post-CAR-T patients.

Risks

• Increased risk of therapy-related myeloid neoplasms in patients with extensive prior exposure to cytotoxic regimens.

Patient & Prescribing Data

Elderly patients with refractory diffuse large B-cell lymphoma.

Combination therapy may lead to severe myelosuppression, necessitating careful management.

Clinical Best Practices

• Prompt evaluation of persistent cytopenia post-CAR-T therapy.
• Incorporation of genetic testing in the diagnostic workup for suspected therapy-related myeloid neoplasms.

Related Resources & Content